CVS Health director receives 1,447-share stock grant

CVS Health Corp director Guy P. Sansone received a stock grant as part of his board compensation.

Rhea-AI Filing Summary

CVS Health Corp director Guy P. Sansone received a stock grant as part of his board compensation. He acquired 1,447 shares of common stock valued at $97.15 per share, issued in payment of a semi-annual retainer at the market price under the 2017 Incentive Compensation Plan. Following this grant, he directly holds 15,106.355 CVS shares.

Insider Trade Summary

Grant/Award: 1,447 shares

Grant/Award 1 txn

Insider SANSONE GUY P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,447	$97.15	$141K

Holdings After Transaction: Common Stock — 15,106.355 shares (Direct)

Footnotes (1)

1. F1. Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.

Key Figures

Stock grant size: 1,447 shares Reference price per share: $97.15 per share Post-transaction holdings: 15,106.355 shares

3 metrics

Stock grant size 1,447 shares Common Stock award to director Guy P. Sansone

Reference price per share $97.15 per share Value used for semi-annual retainer stock grant

Post-transaction holdings 15,106.355 shares Direct CVS holdings after the grant

Key Terms

2017 Incentive Compensation Plan, semi-annual retainer, Common Stock

3 terms

2017 Incentive Compensation Plan financial

"pursuant to the 2017 Incentive Compensation Plan."

semi-annual retainer financial

"issued in payment of a semi-annual retainer, at the market price"

Common Stock financial

"Consists of common stock issued in payment of a semi-annual retainer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CVS (CVS) director Guy P. Sansone report in this Form 4?

Guy P. Sansone reported receiving 1,447 CVS common shares as a stock grant. The award represents payment of a semi-annual director retainer at market price under the 2017 Incentive Compensation Plan and increases his direct holdings to 15,106.355 shares.

Was the CVS (CVS) Form 4 transaction a market purchase or a grant?

The Form 4 shows a grant or award acquisition, not a market purchase. The 1,447 CVS shares were issued as compensation for a semi-annual retainer, at market price, under the 2017 Incentive Compensation Plan rather than being bought on the open market.

How many CVS (CVS) shares did Guy P. Sansone receive in this award?

He received 1,447 CVS common shares. The filing lists the transaction code as an award grant, with a value reference of $97.15 per share, reflecting the market price used to calculate the semi-annual retainer compensation.

What are Guy P. Sansone’s CVS (CVS) holdings after this reported grant?

After the grant, Guy P. Sansone directly holds 15,106.355 CVS common shares. This total incorporates the 1,447-share award received as payment of a semi-annual director retainer under the company’s 2017 Incentive Compensation Plan.

Under which plan was the CVS (CVS) director stock grant issued?

The 1,447 CVS common shares were issued under the 2017 Incentive Compensation Plan. According to the filing, they were granted at the market price as payment of a semi-annual retainer for Guy P. Sansone’s service on the company’s board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 05:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANSONE GUY P

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RHODE ISLAND 02895

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		1,447	A	$97.15	15,106.355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan.

	/s/ Guy P. Sansone	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)